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explants were pre-incubated with the ALK5 inhibitor SB-505124 (50mM)
for 6 hours. Expression of MMP13, ALK5 and ALK1 was analyzed by
quantitative PCR.
Results: Staining for both SMAD2/3P and SMAD1/5/8P was observed in
human OA cartilage. Strikingly, SMAD2/3P staining was mostly negative
in histological intact cartilage areas while cells in damaged areas, mainly
in chondrocyte clusters, were often strongly positive. Also staining for
SMAD1/5/8P was most intense in cells surrounding damaged regions and
chondrocyte clusters. Incubation of human OA cartilage with TGF beta
signiﬁcantly down regulated MMP13 expression. This effect was totally
abolished by the ALK5 inhibitor SB-505124. TGF beta also signiﬁcantly
elevated ALK5 expression, and decreased ALK1 expression, and both
these effects were completely blocked by pre-incubation with SB-
505124.
Conclusion: Stimulation of human end-stage OA cartilage with high TGF
beta concentrations down regulates MMP13 expression and modulates
TGF beta type I receptors, increasing the ALK5/ALK1 ratio. These effects
all run via SMAD2/3 (ALK5). We propose, based on these results and
earlier ﬁndings, that during aging TGF beta loses its protective role
by a loss of SMAD2/3 signaling in articular chondrocytes. This loss
plays a role in the initiation of cartilage degradation. In end-stage
OA cartilage the majority of cells does not display either SMAD2/3P
or SMAD1/5/8P. However, neighboring severely damaged cartilage a
population of chondrocytes is present, most probably involved in
(unsuccessful) repair, that expresses SMAD2/3P and SMAD1/5/8P.
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Purpose: Developmental dysplasia of hip (DDH) is recognized as a
potential risk factor for hip pain in young adults and a risk factor
for development of hip osteoarthritis (OA). Recently, femoroacetabular
impingement (FAI), with other dysmorphic and orientation abnormalities
of the hip joint, has been reported. Both conditions were presumed to be
in an early stage of degeneration based on their long term history and
radiographic evaluations, however, there are no reports of a biological
basis for early OA or discrimination of DDH and FAI. Therefore, the
purpose of this study was to determine the metabolic proﬁle of the
cartilage at the time of hip surgery to reshape the hip.
Methods: Fifty nine cartilage samples were obtained from patients
who had FAI (n = 26), DDH (n=13), and structural instability with
impingement (combined) (n = 20), at the time of their joint preservation
surgery, either surgical dislocation or/and periacetabular osteotomy.
Cartilage samples from 2 children were used as normal control, and
7 OA samples were used as disease controls. All cartilage samples were
harvested from their femoral neck junctions, and RNAs were extracted.
These cartilage samples were evaluated by real-time PCR assay of
gene expression of cytokines and chemokines, matrix molecules, and
degradative enzymes. The macroscopic cartilage damage was classiﬁed
by Beck’s criteria (normal, malacia, cleavage, and defect).
Results: RNA from both diseases presented high levels of speciﬁc
inﬂammatory cytokines (IL-1b and IL-8), chemokines (CXCL2, CXCL3,
CXCL6, CCL3 and CCL3L1), and degenerative mediators (MMP-13 and
ADAMTS-4), and this expression was higher in FAI than DDH or
combined. In addition, expression of Type II collagen (Col2A1) and
Aggrecan were higher in FAI compared to DDH and combined samples
(Figure 1).
Stratiﬁcation by age (<20 y.o., ≥20 y.o.) showed that older DDH and
combined samples expressed higher levels of some chemokines (CCL3L1
in DDH, CXCL1 and CXCL2 in combined) and catabolic enzymes (MMP-
13 in DDH, ADAMTS-4 in combined). In addition, the Col2A1 level was
lower in older samples (Figure 2).
Comparison between Beck’s classiﬁcation showed a higher expression of
a speciﬁc cytokine (IL-8), chemokines (CXCL1, CXCL3, CXCL6, and CCL3L1),
and ADAMTS-4 in samples with cartilage cleavage. Col2A1 expression
was gradually increased with advancing cartilage damage, while less
expression in OA samples.
Conclusions: The cartilage condition in both diseases is considered pre-
OA, based on the lack of radiographic OA. The cartilage of FAI has a high
level of metabolic activity with more arthritic character (high catabolic
factors) but also a regenerative response (high Col2A1 and Aggrecan).
In both DDH and combined patients, the overall level of metabolic
activity was lower than FAI, however the expression of degenerative
enzymes was age-dependent indicating cartilage degradation especially
in older patients. Therefore, both age and OA-related symptoms need
to be taken into account when considering surgical intervention. We
hypothesize that joint preservation surgery would decrease stress on
the articular cartilage and lower metabolic activity. In conclusion, we
have demonstrated that hip cartilage from young patients with FAI and
DDH has a unique biological character, which may lead to identiﬁcation
of speciﬁc biomarkers for detection of early degenerative changes and
outcomes following treatment.
Fig. 1. Expression levels of cytokines, matrix molecules, and chemokines
in FAI, DDH and combined samples. RNA expression was normalized
to GAPDH mRNA and then compared with normal cartilage samples
(set at 1). *Signiﬁcant difference between normal control.
Fig. 2. Stratiﬁcation by age (<20 y.o., ≥20 y.o.) in each disease. RNA
expression was normalized to GAPDH mRNA and then compared with
normal cartilage samples (set at 1). *Signiﬁcant difference between each
age group.
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Purpose: Osteoarthritis is the most common chronic joint disorder in
the US, affecting nearly one-tenth of the population. It is characterized
by degeneration of the articular cartilage, limited intra-articular
inﬂammation and synovitis, changes in sub-chondral bone and pain.
Nothing in the current standard of care preserves cartilage or carries a
claim of disease modiﬁcation in osteoarthritis; standard treatments focus
on symptom relief using NSAIDs, injected steroids, and viscosupplements.
IL-1, produced by chondrocytes in OA cartilage, promotes increased
expression and activation of aggrecanases and matrix metalloproteinases
